Vanda Strikes Out at the Supreme Court
April 22, 2024, 3:57 PM
Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable expectation of success” standard for patent obviousness that for decades has been a mainstay of patent law.
Vanda argued that the Court should instead adopt a “predictable results” standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda’s petition, leaving the obviousness standard unchanged.
To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
Stakeholders 24th Annual CYOC Career Development Conference
Sponsorship
CompLaw 33rd Annual Advanced EU Brussels Conference
Speaking Engagement
ALM General Counsel Conference East 2024
Speaking Engagement
Antitrust
Global Legal Group Global Class Actions Symposium 2024
Speaking Engagement
Litigation & Trials
NAPABA Convention 2024
Sponsorship
Kisaco Research Pharma and Biotech Patent Litigation 2024
Speaking Engagement
Intellectual Property
AIJA IP/TMT Seminar // 11th Antitrust Annual Conference
Speaking Engagement
Antitrust
EDTX Bench Bar Conference 2024
Sponsorship
Antitrust
Informa Connect Antitrust Texas Conference 2024
Speaking Engagement
Antitrust
LSPN North America Fall Conference 2024
Speaking Engagement
Intellectual Property